Sign in Register

Indication

Hypercalcemia due to primary hyperparathyroidism

Hypercalcemia due to primary hyperparathyroidism is an endocrine condition marked by elevated serum calcium concentrations resulting from the autonomous, unregulated overproduction of parathyroid hormone (PTH) by one or more abnormal parathyroid glands, most frequently a benign solitary adenoma. Read more about Hypercalcemia due to primary hyperparathyroidism

19 drugs 16 manufacturers

Advertisement

Drugs that treat it

Common Hypercalcemia due to primary hyperparathyroidism therapies.

Showing 1–9 of 19 drugs

SENSIPAR (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
AMGEN

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
CIPLA USA, INC.

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
SLATE RUN PHARM

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Mylan Pharmaceuticals

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
ASCEND LABORATO

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
STRIDES PHARMA

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Mylan Pharmaceuticals

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Major Pharamceuticals
Filter & compare in the drug finder →Opens the drug finder with Hypercalcemia due to primary hyperparathyroidism preselected.

News & literature

Coming soon

Related codes

Coming soon

Related conditions & guidelines

Coming soon

About Hypercalcemia due to primary hyperparathyroidism.

Hypercalcemia due to primary hyperparathyroidism is an endocrine condition marked by elevated serum calcium concentrations resulting from the autonomous, unregulated overproduction of parathyroid hormone (PTH) by one or more abnormal parathyroid glands, most frequently a benign solitary adenoma.

It primarily affects adults—most commonly postmenopausal women—and involves disrupted calcium homeostasis across the skeletal, renal, and gastrointestinal systems.

Pathophysiologically, inappropriate excess PTH stimulates osteoclastic bone resorption, increases renal tubular reabsorption of calcium, and enhances 1,25-dihydroxyvitamin D synthesis to promote intestinal calcium absorption.

Clinically, it ranges from asymptomatic hypercalcemia detected on routine blood testing to overt disease manifesting with nephrolithiasis, decreased bone mineral density, osteopenia, bone fractures, and neuromuscular or neuropsychiatric symptoms.

Personalize your experience

Follow Hypercalcemia due to primary hyperparathyroidism and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it